Fluorine-18 Market Share, Size, and Forecast | 2030
市场洞察和分析师观点:
氟 18 是一种用于医疗诊断程序的放射性同位素,也是最常用的医用放射性同位素之一全球。它具有良好的正电子发射性能,半衰期为109.8分钟。慢性病的高患病率和核成像技术的日益使用等因素推动了 18 氟市场的增长。然而,氟18的保质期短阻碍了市场的增长。此外,放射性示踪剂在癌症诊断中的使用预计将在未来几年带来新的氟 18 市场趋势。
增长动力:
越来越多地使用核成像技术推动市场增长
先进的辐射技术已经在诊断和核医学、放射治疗和介入放射学领域开辟了新的视野。电离辐射在诊断和治疗中的应用使全球数百万患者受益。正电子发射断层扫描 (PET) 是临床环境中常用的核医学放射学方式,因为它有助于准确检测、定位和表征疾病。据世界卫生组织 (WHO) 统计,全球每年进行超过 36 亿次放射诊断检查、3700 万次核医学手术和 750 万次放射治疗。根据欧盟委员会的数据,欧洲每年使用放射性药物和成像仪器进行约 1000 万次核医学手术,以诊断疾病并提供有针对性的治疗。这些技术也被用于肿瘤学、免疫学、感染研究、胃肠病学、心脏病学、神经病学和精神病学。用于 PET/CT 的新型放射性药物的开发和推出,以及不同肿瘤分期方法的准确性不断提高,促进了 18 氟市场的增长。例如,新推出的心脏放射性药物(如 flurpiridaz F-18)有助于更精确地对心血管疾病进行成像。
报告细分和范围:
氟 18 市场分析是通过考虑以下因素进行的以下部分:产品类型、应用程序和最终用户。按产品类型,市场分为 FDG、NaF 等。 FDG 细分市场在 2022 年占据最大的 18 氟市场份额,预计在预测期内复合年增长率最高。
按产品类型划分的 18 氟市场 – 2022 年和 2030 年
18 氟市场按应用领域分为肿瘤科、心脏病科、神经科等。肿瘤学领域在 2022 年占据最大的市场份额,预计在预测期内复合年增长率最高。
按最终用户划分,该市场分为医院、诊断中心等。到 2022 年,医院领域将占据最大的氟 18 市场份额。预计在预测期内复合年增长率最高。
区域分析:
就地理而言,氟 18 市场报告的范围包括北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,北美占据最大的市场份额。由于混合成像等技术的进步、用于诊断和治疗的新型放射性药物的引入以及基于示踪剂原理的分子成像技术的发展,美国核医学取得了显着的发展。先进的医疗基础设施、目标疾病发病率和患病率的上升以及主要参与者的产品创新进一步促进了北美 18 氟市场规模的扩大。根据国际癌症研究机构 (IARC) 的数据,美国癌症病例数量预计将从 2020 年的 228 万例增加到 2040 年的 312 万例。此外,医疗保险和医疗补助服务中心 (CMS) ,美国根据临床实验室改进修正案 (CLIA) 采用了与人体实验室研究相关的标准,这有利于市场进步。
行业发展和未来机遇:
氟行业领先企业的一些战略发展-18个市场如下:
2023年10月,Blue Earth Diagnostics Ltd与新药集团签署了氟妥司他(18F)注射液(原称18F-rhPSMA-7.3)独家战略协议。根据协议条款,两家公司成为密切的战略合作伙伴,共同为患有前列腺癌的中国男性销售 PET 显像剂 flotufolastat (18F) 提供技术和监管支持。这一事件标志着 Blue Earth Diagnostics 向全球患者和临床医生提供 flotufolastat (18F) 战略的重要阶段。2023 年 7 月,欧盟委员会授予 Pylclari 的营销授权,Pylclari 是一种创新的 18F-PSMA PET 示踪剂锔,适用于在临床环境中使用 PET 检测成人前列腺癌患者的 PSMA 阳性(即前列腺特异性膜抗原)病变。2023 年 5 月,Blue Earth Diagnostics 赢得了美国食品和药物管理局的认证(FDA) 批准其优化的高亲和力放射性混合 (rh) PSMA’ 靶向 PET 显像剂——POSLUMA(flotufolastat F 18)注射液(以前称为 18F’ rhPSMA’ 7.3)。 POSLUMA 适用于通过 PET 检测前列腺癌患者中的 PSMA 阳性病变,根据血清前列腺特异性抗原 (SA) 水平升高疑似转移或疑似复发。转移性患者被认为是初始确定性治疗的候选者。 POSLUMA 是第一个也是唯一一个经 FDA 批准的、采用专有 rh 技术开发的 PSMA 靶向显像剂。它于 2023 年 6 月通过 Blue Earth Diagnostics 国家放射性药物网络中的某些放射性药物进行商业化销售,该网络由来自美国的商业制造商和分销商组成。2021 年 5 月,Lantheus Holdings, Inc. 获得 FDA 批准 PYLARIFY,这是一种氟 18 标记的 PSMA 靶向 PET 成像剂用于识别前列腺癌的疑似转移或复发。 PYLARIFY 是第一个也是唯一一个经 FDA 批准的商用 PSMA PET 成像剂,用于治疗前列腺癌。竞争格局和主要公司:
Siemens Healthineers、Lantheus Medical Imaging Inc、Novartis AG、Cardinal Health、GE HealthCare、Jubilant Radiopharma、Eli礼来公司 (Lilly and Company)、Nukleon Nuclear Technology Research Ind Co Ltd、Curium Pharma 和 Blue Earth Diagnostics Inc 是氟 18 市场报告中介绍的知名公司之一。这些公司专注于开发新技术、升级现有产品并扩大其地域分布,以满足全球不断增长的消费者需求。
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
This text is related
to segments covered.
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Fluorine-18 is a fluorine radioisotope used in medical diagnostic procedures and is among the most commonly used medical radioisotopes globally. Fluorine-18 has good positron-emitting properties and a half-life of 109.8 min.
Factors such as the high prevalence of chronic diseases and increasing use of nuclear imaging techniques propel the fluorine-18 market growth.
The fluorine-18 market was valued at US$ 1,720.71 million in 2022.
The fluorine-18 market majorly consists of the players, including Siemens Healthineers, Lantheus Medical Imaging Inc, Novartis AG, Cardinal Health, GE HealthCare, Jubilant Radiopharma, Eli Lilly and Company, Nukleon Nuclear Technology Research Ind Co Ltd, Curium Pharma, and Blue Earth Diagnostics Inc.
The fluorine-18 market is expected to be valued at US$ 2,415.67 million in 2030.
By product type, the fluorine-18 market is segmented into FDG, NaF, and others. The FDG segment held the largest fluorine-18 market share in 2022 and it is anticipated to register the highest CAGR during the forecast period.
The fluorine-18 market, by end users, is categorized into hospitals, diagnostic centers, and others. The hospitals segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period.
The fluorine-18 market, by application, is divided into oncology, cardiology, neurology, and others. The oncology segment held a larger market share in 2022 and is anticipated to register a higher CAGR during the forecast period.
The List of Companies - Fluorine-18 Market
- Siemens Healthineers
- Lantheus Medical Imaging Inc
- Novartis AG
- Cardinal Health
- GE HealthCare
- Jubilant Radiopharma
- Eli Lilly and Company
- Nukleon Nuclear Technology Research Ind Co Ltd
- Curium Pharma
- Blue Earth Diagnostics Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.